Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.

The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.

• Publication year

  2016

• Venue

  Immunotherapy

• Publication date

  2016-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt-2016-0049PMID 27161438
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunosuppression and Post-transplant Hyperglycemia.

  2015cited by this paper
• Oral anti‐CD3 immunotherapy for HCV‐nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase‐2a placebo‐controlled trial

  2015cited by this paper
• Manipulating regulatory T cells: a promising strategy to treat autoimmunity.

  2015cited by this paper
• Heterogeneous CD3 Expression Levels in Differing T Cell Subsets Correlate with the In Vivo Anti-CD3–Mediated T Cell Modulation

  2015cited by this paper
• Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial

  2015cited by this paper
• Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes

  2014cited by this paper
• Efficacy and safety of low‐dose otelixizumab anti‐CD3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: DEFEND‐2, a randomized, placebo‐controlled, double‐blind, multi‐centre study

  2014cited by this paper
• A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease.

  2014cited by this paper
• TGF-β activation and function in immunity.

  2014cited by this paper
• Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice.

  2014cited by this paper
• The importance of regulatory T‐cell heterogeneity in maintaining self‐tolerance

  2014cited by this paper
• Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans.

  2014cited by this paper
• Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes

  2013cited by this paper
• Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the Dominance of Foxp3+CD4+ Graft Infiltrating Cells

  2013cited by this paper
• Generation and Function of Induced Regulatory T Cells

  2013cited by this paper
• Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes

  2013cited by this paper
• Regulatory T cells in nonlymphoid tissues

  2013cited by this paper
• Anti-cytokine therapies in T1D: Concepts and strategies.

  2013cited by this paper
• Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

  2013cited by this paper
• Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

  2012cited by this paper
• CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

  2012cited by this paper
• An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice.

  2012cited by this paper
• Preexisting Autoantibodies Predict Efficacy of Oral Insulin to Cure Autoimmune Diabetes in Combination With Anti-CD3

  2012cited by this paper
• Regulatory T-Cells: Diverse Phenotypes Integral to Immune Homeostasis and Suppression

  2012cited by this paper
• Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients

  2012cited by this paper
• Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing

  2012cited by this paper
• Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments.

  2012cited by this paper
• Induced CD4+Foxp3+ regulatory T cells in immune tolerance.

  2012cited by this paper
• Potent Induction Immunotherapy Promotes Long‐Term Insulin Independence After Islet Transplantation in Type 1 Diabetes

  2012cited by this paper
• Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.

  2012cited by this paper
• TGF-β: the sword, the wand, and the shield of FOXP3(+) regulatory T cells.

  2012cited by this paper
• Oral tolerance

  2011cited by this paper
• Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance

  2011cited by this paper
• Induction of Immunological Tolerance by Oral Anti-CD3

  2011cited by this paper
• Control of TH17 cells occurs in the Small Intestine

  2011cited by this paper
• Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells

  2011cited by this paper
• Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

  2011cited by this paper
• Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade

  2011cited by this paper
• In Vivo Induction of Tr1 Cells via Mucosal Dendritic Cells and AHR Signaling

  2011cited by this paper
• Sub‐optimal CD4+ T‐cell activation triggers autonomous TGF‐β‐dependent conversion to Foxp3+ regulatory T cells

  2011cited by this paper
• Report of a Joint ESOT and AST Meeting: Highlights in Biologic Agents and Transplantation

  2011cited by this paper
• Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.

  2011cited by this paper
• Type 1 regulatory T cells (Tr1) in autoimmunity.

  2011cited by this paper
• Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

  2010cited by this paper
• Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice

  2010cited by this paper
• Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.

  2010cited by this paper
• Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

  2010cited by this paper
• Phase I, double‐blind, randomized, placebo‐controlled, dose‐escalation study of NI‐0401 (a fully human anti‐CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease†

  2010cited by this paper
• Metrics for antibody therapeutics development

  2010cited by this paper
• Acquisition of regulatory function by human CD8+ T cells treated with anti‐CD3 antibody requires TNF

  2010cited by this paper
• Mucosal Anti-CD3 Monoclonal Antibody Attenuates Collagen-Induced Arthritis That Is Associated with Induction of LAP+ Regulatory T Cells and Is Enhanced by Administration of an Emulsome-Based Th2-Skewing Adjuvant

  2010cited by this paper
• Therapeutic antibodies for autoimmunity and inflammation

  2010cited by this paper
• Oral Anti-CD3 Antibody Treatment Induces Regulatory T Cells and Inhibits the Development of Atherosclerosis in Mice

  2009cited by this paper
• Oral Administration of OKT3 Monoclonal Antibody to Human Subjects Induces a Dose-Dependent Immunologic Effect in T Cells and Dendritic Cells

  2009cited by this paper
• It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response.

  2009cited by this paper
• Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells

  2009cited by this paper
• Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.

  2009cited by this paper
• Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors.

  2009cited by this paper
• Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice

  2009cited by this paper
• Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways.

  2008cited by this paper
• Suppression of Mature Dendritic Cell Function by Regulatory T Cells In Vivo Is Abrogated by CD40 Licensing1

  2008cited by this paper
• Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

  2008cited by this paper
• Latency-Associated Peptide Identifies a Novel CD4+CD25+ Regulatory T Cell Subset with TGFβ-Mediated Function and Enhanced Suppression of Experimental Autoimmune Encephalomyelitis1

  2008cited by this paper
• CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-β–dependent manner

  2008cited by this paper
• CD3-specific antibody–induced immune tolerance involves transforming growth factor-β from phagocytes digesting apoptotic T cells

  2008cited by this paper
• Humanization of antibodies.

  2008cited by this paper
• New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

  2008cited by this paper
• Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II1

  2008cited by this paper
• Molecular engineering and design of therapeutic antibodies.

  2008cited by this paper
• CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes.

  2008cited by this paper
• Nasal Anti-CD3 Antibody Ameliorates Lupus by Inducing an IL-10-Secreting CD4+CD25−LAP+ Regulatory T Cell and Is Associated with Down-Regulation of IL-17+CD4+ICOS+CXCR5+ Follicular Helper T Cells1

  2008cited by this paper
• A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.

  2007cited by this paper
• Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody

  2007cited by this paper
• The inhibitory cytokine IL-35 contributes to regulatory T-cell function

  2007cited by this paper
• Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

  2007cited by this paper
• CD3-specific antibodies: a portal to the treatment of autoimmunity

  2007cited by this paper
• Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

  2007cited by this paper
• FOXP3: of mice and men.

  2006cited by this paper
• Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells

  2006cited by this paper
• Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells.

  2006cited by this paper
• A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

  2005cited by this paper
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

  2005cited by this paper
• Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis1

  2005cited by this paper
• CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications.

  2005cited by this paper
• The ICOS Molecule Plays a Crucial Role in the Development of Mucosal Tolerance1

  2005cited by this paper
• Inducing and expanding regulatory T cell populations by foreign antigen

  2005cited by this paper
• Transplantation of Cultured Islets from Two‐Layer Preserved Pancreases in Type 1 Diabetes with Anti‐CD3 Antibody

  2004cited by this paper
• In Vivo Instruction of Suppressor Commitment in Naive T Cells

  2004cited by this paper
• Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors.

  2004cited by this paper
• TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

  2003cited by this paper
• Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3

  2003cited by this paper
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)

  2003cited by this paper
• Tolerogenic dendritic cells.

  2003cited by this paper
• Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

  2002cited by this paper
• Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes.

  2001cited by this paper
• Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.

  2001cited by this paper
• Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide

  2001cited by this paper
• Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4.

  2001cited by this paper

• Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

  2026cites this paper
• Synthesis of Immunotoxin of Anti-CD3 Monoclonal Antibody-Bongkrekic Acid and Cytotoxic Effect Against CD3+ T Cells in Peripheral Blood Mononuclear Cells.

  2026cites this paper
• Enhancing Anti-CTLA-4 Antibody Delivery to the Brain Using Focused Ultrasound and Microbubbles

  2026cites this paper
• Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS

  2025cites this paper
• Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer’s Disease Dementia

  2025cites this paper
• Ovalbumin-specific regulatory T cells differentiated from the naïve phenotype (CD44loCD62Lhi) in mesenteric lymph nodes stably suppress enteropathy even in severe food-allergic mice

  2025cites this paper
• Adaptive immunity in the pathogenesis and treatments of Parkinson’s disease

  2025cites this paper
• Activation of the Immunoregulatory Cation Channel TMEM176B by a Nitroalkene Derivative of Salicylate Prolongs Graft Survival.

  2025cites this paper
• Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy

  2025cites this paper
• Enhancing the treatment potential of IL-17 antagonism in lupus nephritis: finding the right partner

  2025cites this paper
• Combining Network Pharmacology, Molecular Docking, and Integrative Studies to Explore the Mechanism of Helminthostachys zeylanica in Alleviating Ulcerative Colitis

  2025cites this paper
• First-in-class anti-human CD45RC antibody targets CD45RChigh T and B cells to mitigate pathogenic immune responses.

  2025cites this paper
• Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes

  2025cites this paper
• Sequence Diversity and Expression Profiles of T Cell Receptor Beta Chain Constant Genes TRBC1 and TRBC2 in Canine Lymphoid Tumour Cell Lines and Normal Lymphocytes

  2025cites this paper
• Synergistic venetoclax and aCD3 therapy for control of alloreactive response in hematopoietic stem cell transplantation.

  2025cites this paper
• Redosing of anti-CD3 antibodies in NOD mice with new-onset diabetes does not alter the effect of a single treatment course

  2025cites this paper
• Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence

  2025cites this paper
• Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer.

  2025cites this paper
• Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemia

  2024cites this paper
• Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies

  2024cites this paper
• Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation

  2024cites this paper
• A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action

  2024cites this paper
• Immune mechanisms and shared immune targets in neurodegenerative diseases

  2024cites this paper
• "Innovations in Cancer Immunotherapy: A Comprehensive Overview of Recent Breakthroughs and Future Directions".

  2024cites this paper
• On the immunotropic effects of a new combined pharmaconutraceutical preparation in osteoarthritis

  2024cites this paper
• First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC

  2024cites this paper
• Level Change of Biochemical Markers in Serum After Acute Administration of Magnetite (Fe₃O₄) Nanoparticles

  2024cites this paper
• Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review

  2024cites this paper
• Low-dose IL-2 treatment confers anti-inflammatory effect against subarachnoid hemorrhage in mice

  2024cites this paper
• B cells and the stressed brain: emerging evidence of neuroimmune interactions in the context of psychosocial stress and major depression

  2024cites this paper
• IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation

  2024cites this paper
• Role of teplizumab, a humanized anti-CD3 monoclonal antibody, in managing newly diagnosed type 1 diabetes: an updated systematic review and meta-analysis.

  2024cites this paper
• Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy

  2024cites this paper
• The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy

  2024cites this paper
• Liposomes: An Emerging Strategy for the Effective Treatment of Rheumatoid Arthritis.

  2024cites this paper
• Revealing Novel Genomic Insights and Therapeutic Targets for Juvenile Idiopathic Arthritis through Omics.

  2024cites this paper
• An Fc Binding Peptide-Based Facile and Versatile Build Platform for Multispecific Antibodies.

  2023cites this paper
• Lymphocyte-Related Immunomodulatory Therapy with Siponimod (BAF-312) Improves Outcomes in Mice with Acute Intracerebral Hemorrhage

  2023influential citation
• Antibody‐Conjugated Magnetic Nanoparticle Therapy for Inhibiting T‐Cell Mediated Inflammation

  2023cites this paper
• A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches

  2023cites this paper
• The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus

  2023cites this paper
• Clinically Approved Monoclonal Antibodies-Based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care.

  2023cites this paper
• Teplizumab in Type 1 Diabetes Mellitus: An Updated Review

  2023cites this paper
• A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells

  2023cites this paper
• Genome Editing in Engineered T Cells for Cancer Immunotherapy

  2023cites this paper
• Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

  2023cites this paper
• Efficacy of anti‐CD3 monoclonal antibodies in delaying the progression of recent‐onset type 1 diabetes mellitus: A systematic review, meta‐analyses and meta‐regression

  2023cites this paper
• Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH.

  2023cites this paper
• BANKED ALLOGENEIC IMMUNE EFFECTOR CELLS Genome-edited allogeneic donor “ universal ” chimeric antigen receptor T cells

  2023cites this paper
• ABBV-184: A novel survivin-specific TCR/CD3 bispecific T cell engager is active against both solid tumor and hematological malignancies.

  2023cites this paper
• Preexisting immunity does not prevent efficacy of VSV-based filovirus vaccines in nonhuman primates.

  2023cites this paper
• Genetic code expansion in E. coli enables production of a functional 'ready-to-click' T cell receptor-specific scFv.

  2023cites this paper
• Bispecific antibodies in cancer therapy: Target selection and regulatory requirements

  2023cites this paper
• Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice.

  2023cites this paper
• Teplizumab Therapy to Delay the Onset of Type 1 Diabetes

  2023cites this paper
• Excitable dynamics of flares and relapses in autoimmune diseases

  2023cites this paper
• Insight Of Engineered Nano-Based Biologics Approaches Used To Combat Autoimmune Disease Using Tnf-Α & Il Inhibitors.

  2023cites this paper
• Anti‐CD3 inhibits circulatory and tissue‐resident memory CD4 T cells that drive asthma exacerbations in mice

  2023cites this paper
• Teplizumab

  2023cites this paper
• Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials

  2023cites this paper
• Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19

  2023cites this paper
• Modulating T Cell Responses by Targeting CD3

  2023influential citation
• Spleen distribution and serum immune responses after acute administration of silica-conjugated magnetite (Fe3O4) nanoparticles

  2023cites this paper
• Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects

  2022cites this paper
• Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells

  2022cites this paper
• The immune response as a therapeutic target in non-alcoholic fatty liver disease

  2022cites this paper
• Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.

  2022cites this paper
• Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential

  2022cites this paper
• The global landscape of approved antibody therapies

  2022cites this paper
• High endothelial venules as potential gateways for therapeutics.

  2022cites this paper
• Therapeutic monoclonal antibodies with a focus on hereditary angioedema.

  2022cites this paper
• The type 1 diabetes immune niche: Immunomodulatory biomaterial design considerations for beta cell transplant therapies

  2022cites this paper
• A Fully-Human Antibody Specifically Targeting a Membrane-Bound Fragment of CADM1 Potentiates the T Cell-Mediated Death of Human Small-Cell Lung Cancer Cells

  2022cites this paper
• Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients

  2022cites this paper
• NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives

  2022cites this paper
• Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer

  2022cites this paper
• Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage

  2022cites this paper
• Emerging local immunomodulatory strategies to circumvent systemic immunosuppression in cell transplantation

  2022cites this paper
• Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

  2022cites this paper
• Research Progress of Regulatory T Cells in Atopic Dermatitis

  2022cites this paper
• Novel potential treatable traits in asthma: Where is the research taking us?

  2022cites this paper
• Oral tolerance: an updated review.

  2022cites this paper
• Magnetic Resonance Imaging of Tumor‐Infiltrating Lymphocytes by Anti‐CD3‐Conjugated Iron Oxide Nanoparticles

  2022cites this paper
• Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer

  2022cites this paper
• Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1

  2021cites this paper
• The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities

  2021cites this paper
• Calcium signaling on Jurkat T cells induced by microbeads coated with novel peptide ligands specific to human CD3ε.

  2021cites this paper
• A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties

  2021cites this paper
• Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy

  2021cites this paper
• Neuroinflammation in Parkinson’s Disease: Triggers, Mechanisms, and Immunotherapies

  2021cites this paper
• Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy.

  2021cites this paper
• Oral delivery of therapeutic proteins bioencapsulated in plant cells: preclinical and clinical advances.

  2021cites this paper
• Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation

  2021cites this paper
• Ovalbumin antigen-specific activation of T cell receptor closely resembles soluble antibody stimulation as revealed by BOOST phosphotyrosine proteomics

  2021cites this paper
• Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII

  2021cites this paper
• Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

  2021cites this paper
• Preventing type 1 diabetes in childhood

  2021cites this paper
• Transient Depletion of Foxp3+ Regulatory T Cells Selectively Promotes Aggressive β Cell Autoimmunity in Genetically Susceptible DEREG Mice

  2021cites this paper
• Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

  2021cites this paper
• Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells

  2021cites this paper